These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20506947)

  • 1. P53 expression as a prognostic marker in giant cell tumor of bone: a pilot study.
    Papanastassiou I; Ioannou M; Papagelopoulos PJ; Arealis G; Mihas C; Iakovidou I; Demertzis N
    Orthopedics; 2010 May; 33(5):. PubMed ID: 20506947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases.
    Pazzaglia L; Conti A; Chiechi A; Novello C; Magagnoli G; Astolfi A; Pession A; Krenacs T; Alberghini M; Picci P; Benassi MS
    Histopathology; 2010 Jul; 57(1):59-72. PubMed ID: 20653781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
    Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
    Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
    Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
    J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of de novo secondary malignant giant-cell tumor of bone with loss of heterozygosity of p53 gene that transformed within a short-term follow-up.
    Saito T; Mitomi H; Suehara Y; Okubo T; Torigoe T; Takagi T; Kaneko K; Yao T
    Pathol Res Pract; 2011 Oct; 207(10):664-9. PubMed ID: 21924561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis.
    Moskovszky L; Szuhai K; Krenács T; Hogendoorn PC; Szendroi M; Benassi MS; Kopper L; Füle T; Sápi Z
    Genes Chromosomes Cancer; 2009 Jun; 48(6):468-79. PubMed ID: 19242928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
    Ständer M; Peraud A; Leroch B; Kreth FW
    Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
    Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
    J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
    Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
    Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic relevance of proliferation marker Ki-67 (MIB 1), PCNA and p53 in combined surgically and radiologically treated cancers of the oropharynx and mouth cavity].
    Sittel C; Ruiz S; Kvasnicka HM; Volling P; Jungehülsing M; Eckel HE
    Laryngorhinootologie; 2000 Feb; 79(2):86-92. PubMed ID: 10738715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors.
    Addeo R; Crisci S; D'Angelo V; Vincenzi B; Casale F; Pettinato G; Donofrio V; Boldrini R; Alaggio R; Collini P; Bertorelle R; Di Tullio MT; Caraglia M; Terenziani M; Lo Curto M; Indolfi P
    Oncol Rep; 2007 May; 17(5):1155-61. PubMed ID: 17390059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.
    Antonescu CR; Tschernyavsky SJ; Decuseara R; Leung DH; Woodruff JM; Brennan MF; Bridge JA; Neff JR; Goldblum JR; Ladanyi M
    Clin Cancer Res; 2001 Dec; 7(12):3977-87. PubMed ID: 11751490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications.
    Nathan CO; Sanders K; Abreo FW; Nassar R; Glass J
    Cancer Res; 2000 Jul; 60(13):3599-604. PubMed ID: 10910074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
    Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
    Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
    Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
    Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
    Tzai TS; Tsai YS; Chow NH
    Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
    Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
    Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.